Page last updated: 2024-08-17

quinidine and fluvoxamine

quinidine has been researched along with fluvoxamine in 26 studies

Research

Studies (26)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	5 (19.23)	18.2507
2000's	11 (42.31)	29.6817
2010's	10 (38.46)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Topliss, JG; Yoshida, F	1
Dormann, SM; Haefeli, WE; Kerpen, CJ; Ketabi-Kiyanvash, N; Martin-Facklam, M; Weiss, J	1
Afzelius, L; Andersson, TB; Baroni, M; Cruciani, G; Karlén, A; Masimirembwa, CM; Mecucci, S; Zamora, I	1
Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL	1
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A	1
Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM	1
Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ	1
Glen, RC; Lowe, R; Mitchell, JB	1
Ekins, S; Williams, AJ; Xu, JJ	1
Cooper, J; Cui, Y; Fink, M; Gavaghan, DJ; Heath, BM; McMahon, NC; Mirams, GR; Noble, D; Sher, A	1
Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR	1
Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B	1
Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY	1
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K	1
Li, H; Martásek, P; Poulos, TL; Qin, Y; Roman, LJ; Silverman, RB; Wang, HY	1
Brøsen, K; Skjelbo, E	1
Belpaire, FM; Brøsen, K; Rasmussen, BB; Temmerman, A; Wijnant, P	1
Brøsen, K; Damkier, P; Hansen, LL	1
Linnet, K; Olesen, OV	1
Bertilsson, L; Ericsson, O; Gustafsson, LL; Hellgren, U; Mirghani, RA; Westerberg, PA	1
Bertilsson, L; Ericsson, O; Gustafsson, LL; Mirghani, RA; Tybring, G	1
Bertilsson, L; Ericsson, O; Gustafsson, LL; Hellgren, U; Mirghani, RA	1
Mäenpää, J; Pelkonen, O; Tolonen, A; Turpeinen, M; Uusitalo, J; Volotinen, M	1
Miura, M; Ohkubo, T	1
Margulis, M; Sorota, S	1
Coelho, EB; Lanchote, VL; Rocha, A	1

Reviews

1 review(s) available for quinidine and fluvoxamine

Article	Year
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans. Drug discovery today, 2016, Volume: 21, Issue:4 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk	2016

Trials

4 trial(s) available for quinidine and fluvoxamine

Article	Year
Effect of fluvoxamine on the pharmacokinetics of quinidine. European journal of clinical pharmacology, 1999, Volume: 55, Issue:6 Topics: Anti-Arrhythmia Agents; Aryl Hydrocarbon Hydroxylases; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP1A2 Inhibitors; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Enzyme Inhibitors; Fluvoxamine; Humans; Male; Metabolic Clearance Rate; Quinidine; Steroid 16-alpha-Hydroxylase; Steroid Hydroxylases	1999
The roles of cytochrome P450 3A4 and 1A2 in the 3-hydroxylation of quinine in vivo. Clinical pharmacology and therapeutics, 1999, Volume: 66, Issue:5 Topics: Adult; Antifungal Agents; Antimalarials; Area Under Curve; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Female; Fluvoxamine; Humans; Hydroxylation; Ketoconazole; Male; Mixed Function Oxygenases; Quinidine; Quinine; Selective Serotonin Reuptake Inhibitors	1999
Quinine 3-hydroxylation as a biomarker reaction for the activity of CYP3A4 in man. European journal of clinical pharmacology, 2003, Volume: 59, Issue:1 Topics: Adult; Biomarkers; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Drug Interactions; Female; Fluvoxamine; Humans; Hydroxylation; Isoenzymes; Ketoconazole; Male; Middle Aged; Quinidine; Quinine	2003
Metabolism and elimination of quinine in healthy volunteers. European journal of clinical pharmacology, 2003, Volume: 59, Issue:5-6 Topics: Antimalarials; Area Under Curve; Aryl Hydrocarbon Hydroxylases; Benzoquinones; Chromatography, High Pressure Liquid; Cross-Over Studies; Cytochrome P-450 CYP1A2; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Fluvoxamine; Humans; Ketoconazole; Mixed Function Oxygenases; Quinidine; Quinine; Quinones; Time Factors	2003

Other Studies

21 other study(ies) available for quinidine and fluvoxamine

Article	Year
QSAR model for drug human oral bioavailability. Journal of medicinal chemistry, 2000, Jun-29, Volume: 43, Issue:13 Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship	2000
Inhibition of P-glycoprotein by newer antidepressants. The Journal of pharmacology and experimental therapeutics, 2003, Volume: 305, Issue:1 Topics: Animals; Antidepressive Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Endothelium, Vascular; Humans; Reproducibility of Results; Swine; Transfection	2003
Conformer- and alignment-independent model for predicting structurally diverse competitive CYP2C9 inhibitors. Journal of medicinal chemistry, 2004, Feb-12, Volume: 47, Issue:4 Topics: Amino Acids; Aryl Hydrocarbon Hydroxylases; Binding Sites; Cytochrome P-450 CYP2C9; Enzyme Inhibitors; Models, Molecular; Molecular Conformation; Molecular Structure; Quantitative Structure-Activity Relationship	2004
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling. Current drug discovery technologies, 2004, Volume: 1, Issue:4 Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration	2004
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species. Chemical research in toxicology, 2010, Volume: 23, Issue:1 Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship	2010
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models. Toxicology mechanisms and methods, 2008, Volume: 18, Issue:2-3 Topics:	2008
Developing structure-activity relationships for the prediction of hepatotoxicity. Chemical research in toxicology, 2010, Jul-19, Volume: 23, Issue:7 Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes	2010
Predicting phospholipidosis using machine learning. Molecular pharmaceutics, 2010, Oct-04, Volume: 7, Issue:5 Topics: Animals; Artificial Intelligence; Databases, Factual; Drug Discovery; Humans; Lipidoses; Models, Biological; Phospholipids; Support Vector Machine	2010
A predictive ligand-based Bayesian model for human drug-induced liver injury. Drug metabolism and disposition: the biological fate of chemicals, 2010, Volume: 38, Issue:12 Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands	2010
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk. Cardiovascular research, 2011, Jul-01, Volume: 91, Issue:1 Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; Dogs; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; HEK293 Cells; Humans; Ion Channels; Kinetics; Models, Cardiovascular; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Potassium Channel Blockers; Rabbits; Risk Assessment; Risk Factors; Sodium Channel Blockers; Sodium Channels; Torsades de Pointes; Transfection	2011
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions. Journal of medicinal chemistry, 2012, May-24, Volume: 55, Issue:10 Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection	2012
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment. Journal of applied toxicology : JAT, 2012, Volume: 32, Issue:10 Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers	2012
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds. Chemical research in toxicology, 2012, Oct-15, Volume: 25, Issue:10 Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding	2012
Potent and Selective Human Neuronal Nitric Oxide Synthase Inhibition by Optimization of the 2-Aminopyridine-Based Scaffold with a Pyridine Linker. Journal of medicinal chemistry, 2016, 05-26, Volume: 59, Issue:10 Topics: Aminopyridines; Dose-Response Relationship, Drug; Enzyme Inhibitors; Humans; Molecular Structure; Nitric Oxide Synthase Type I; Structure-Activity Relationship	2016
Inhibitors of imipramine metabolism by human liver microsomes. British journal of clinical pharmacology, 1992, Volume: 34, Issue:3 Topics: Cytochrome P-450 CYP2D6; Cytochrome P-450 Enzyme Inhibitors; Fluvoxamine; Humans; Hydroxylation; Imipramine; In Vitro Techniques; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Polymorphism, Genetic; Quinidine; Selective Serotonin Reuptake Inhibitors	1992
The oxidative metabolism of metoprolol in human liver microsomes: inhibition by the selective serotonin reuptake inhibitors. European journal of clinical pharmacology, 1998, Volume: 54, Issue:3 Topics: 1-Naphthylamine; Adult; Anti-Arrhythmia Agents; Child; Citalopram; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Fluoxetine; Fluvoxamine; Humans; Hydroxylation; Kinetics; Male; Methylation; Metoprolol; Microsomes, Liver; Oxidation-Reduction; Paroxetine; Quinidine; Selective Serotonin Reuptake Inhibitors; Sertraline	1998
Studies on the stereoselective metabolism of citalopram by human liver microsomes and cDNA-expressed cytochrome P450 enzymes. Pharmacology, 1999, Volume: 59, Issue:6 Topics: Citalopram; Cytochrome P-450 Enzyme System; DNA, Complementary; Fluvoxamine; Gene Expression; Humans; Ketoconazole; Kinetics; Methylation; Microsomes, Liver; Oxidation-Reduction; Quinidine; Recombinant Proteins; Stereoisomerism	1999
Timolol metabolism in human liver microsomes is mediated principally by CYP2D6. Drug metabolism and disposition: the biological fate of chemicals, 2007, Volume: 35, Issue:7 Topics: Adrenergic beta-Antagonists; Aryl Hydrocarbon Hydroxylases; Biotransformation; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Dealkylation; Dextromethorphan; Drug Interactions; Enzyme Inhibitors; Fluvoxamine; Humans; Hydroxylation; In Vitro Techniques; Kinetics; Microsomes, Liver; Mixed Function Oxygenases; Models, Biological; Molecular Structure; Oxidation-Reduction; Quinidine; Recombinant Proteins; Spectrometry, Mass, Electrospray Ionization; Tandem Mass Spectrometry; Timolol	2007
Identification of human cytochrome P450 enzymes involved in the major metabolic pathway of fluvoxamine. Xenobiotica; the fate of foreign compounds in biological systems, 2007, Volume: 37, Issue:2 Topics: Alcohol Dehydrogenase; Amino Acids; Biotransformation; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP2D6 Inhibitors; Cytochrome P-450 Enzyme System; Enzyme Inhibitors; Fluvoxamine; Humans; In Vitro Techniques; Kinetics; Microsomes, Liver; Oxidation-Reduction; Quinidine; Recombinant Proteins	2007
Additive effects of combined application of multiple hERG blockers. Journal of cardiovascular pharmacology, 2008, Volume: 51, Issue:6 Topics: Animals; Cell Culture Techniques; Cisapride; Drug Synergism; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Fluvoxamine; Humans; Mice; Patch-Clamp Techniques; Quinidine; Scorpion Venoms	2008
Influence of quinidine, fluvoxamine, and ketoconazole on the enantioselective pharmacokinetics of citalopram in rats. Canadian journal of physiology and pharmacology, 2008, Volume: 86, Issue:11 Topics: Animals; Antifungal Agents; Antimalarials; Citalopram; Drug Interactions; Fluvoxamine; Ketoconazole; Male; Quinidine; Rats; Rats, Wistar; Selective Serotonin Reuptake Inhibitors; Stereoisomerism	2008